Upregulation of plasma CCL8 in mouse model of graft-vs-host disease.
OBJECTIVE
Using a proteomic approach, we recently identified plasma CCL8 as a potential biomarker for diagnosis of graft-vs-host-disease (GVHD) in mice as well as humans. Because mass spectrometric analysis is only semi-quantitative, a quantitative method of measuring plasma CCL8 levels in mice is needed.


METHODS
We established an enzyme-linked immunosorbent assay for the quantitative measurement of CCL8 concentrations in mouse plasma.


RESULTS
Our newly established enzyme-linked immunosorbent assay revealed that the plasma CCL8 concentrations (mean +/- standard error; n=12) were 1287+/-55.7 ng/mL and 1604+/-110.8 ng/mL on days 7 and 14 after allogeneic bone marrow transplantation (BMT), respectively, while the plasma concentrations was 316.6+/-16.3 ng/mL on day 7 after syngeneic BMT. A Western blotting analysis also showed a difference in the plasma CCL8 levels between the allogeneic and syngeneic BMT groups, as did clinical GVHD scores. Neither lipopolysaccharide nor poly(I:C) elevated the plasma CCL8 concentrations, although a dramatic increase in interleukin-6 was detected after both treatments.


CONCLUSIONS
An elevated plasma CCL8 concentration may be a promising plasma marker for GVHD in mouse models.
Ota
Akinobu
A
Immuno-Biological Laboratories Co. Ltd., Gunma, Japan. do-ota@ibl-japan.co.jp
Yamamoto
Masaki
M
Hori
Tsukasa
T
Miyai
Shunsuke
S
Naishiro
Yasuyoshi
Y
Sohma
Hitoshi
H
Maeda
Masahiro
M
Kokai
Yasuo
Y
D000818:Animals; D015415:Biomarkers / Q000097:blood / Q000378:metabolism; D015153:Blotting, Western; D054412:Chemokine CCL8 / Q000097:blood* / Q000235:genetics / Q000378:metabolism*; D003001:Cloning, Molecular; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006086:Graft vs Host Disease / Q000503:physiopathology*; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D015854:Up-Regulation
D015415:Biomarkers; D054412:Chemokine CCL8